Gastric Cancer Therapy Market Report 2025

The gastric cancer therapy market size has grown strongly in recent years. It will grow from $4.12 billion in 2024 to $4.5 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth during the historical period can be attributed to the rising prevalence of H. pylori infection, increased tobacco and alcohol use, an expanding aging population, limited availability of early diagnostic methods, and the broad adoption of chemotherapy.

The gastric cancer therapy market size is expected to see strong growth in the next few years. It will grow to $6.39 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The projected growth in the forecast period can be attributed to the rise of biomarker-based therapies, an increase in combination treatment strategies, growing investment in oncology research and development, expansion of healthcare infrastructure in emerging markets, and the adoption of liquid biopsies for monitoring. Key trends expected during this period include advancements in personalized medicine, emphasis on targeted drug delivery systems, a surge in clinical trials for new antibodies, integration of AI in diagnostic imaging, and the development of combination therapies.

The increasing prevalence of Helicobacter pylori infection is expected to drive the growth of the gastric cancer therapy market in the future. Helicobacter pylori is a bacterial infection that primarily affects the stomach lining and is a major cause of chronic gastritis and gastric cancer. The rise in Helicobacter pylori infections is mainly attributed to poor sanitation, as inadequate hygiene and contaminated food or water promote oral-oral or fecal-oral transmission of the bacteria. Gastric cancer therapy helps lower the risk of gastric cancer caused by Helicobacter pylori by treating the infection, reducing gastric inflammation and cellular damage, and preventing the progression from chronic gastritis and atrophic changes to malignant transformation of the stomach lining. For example, a report published by the Government of Canada in November 2024 stated that as of January 2023, the recurrence rate of H. pylori infection is estimated to be up to 19%, although this varies depending on geographic location and age. Thus, the growing prevalence of Helicobacter pylori infection is propelling the gastric cancer therapy market.

Leading companies in the gastric cancer therapy market are focusing on innovative treatments such as combination therapy to enhance treatment effectiveness and improve patient outcomes. Combination therapy uses two or more treatments - such as chemotherapy, targeted therapy, or immunotherapy - together to increase overall efficacy. In December 2024, BeOne Medicines Ltd., a China-based pharmaceutical company formerly known as BeiGene, received U.S. Food and Drug Administration (FDA) approval for Tevimbra (tislelizumab-jsgr) combined with platinum- and fluoropyrimidine-based chemotherapy as a first-line treatment for adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma whose tumors express PD-L1 (≥1). This approval was based on the Phase 3 RATIONALE-305 trial, which showed that the combination therapy improved median overall survival to 15 months compared to 12.9 months with chemotherapy alone, representing a 20% reduction in the risk of death. This achievement reflects a growing trend among pharmaceutical companies to invest in multimodal treatments that combine immunotherapy with traditional chemotherapy to improve clinical results, delay disease progression, and extend survival in advanced gastric cancer patients.

In January 2023, Leap Therapeutics Inc., a U.S.-based biotechnology firm, acquired Flame Biosciences Inc. for an undisclosed amount. This acquisition aims to bolster Leap Therapeutics’ oncology pipeline by adding Flame Biosciences’ clinical-stage anti-Claudin18.2 antibody FL-301 and two preclinical antibody programs, advancing the development of biomarker-targeted cancer therapies. Flame Biosciences Inc. is a U.S.-based biotechnology company specializing in gastric cancer therapies.

Major players in the gastric cancer therapy market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Astellas Pharma Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene Ltd., Celltrion Healthcare Co. Ltd., Hutchison MediPharma Limited, Shanghai Henlius Biotech Inc., Imugene Limited, and LintonPharm Co. Ltd.

North America was the largest region in the gastric cancer therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastric cancer therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the gastric cancer therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gastric cancer therapy market consists of revenues earned by entities by providing services such as diagnostic testing and imaging, supportive care and palliative services, and clinical trial and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastric cancer therapy market also includes sales of trastuzumab (Herceptin), nivolumab (Opdivo), ramucirumab (Cyramza), and fluorouracil-based chemotherapy, and endoscopic devices and imaging systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The gastric cancer therapy market research report is one of a series of new reports that provides gastric cancer therapy market statistics, including the gastric cancer therapy industry global market size, regional shares, competitors with the gastric cancer therapy market share, detailed gastric cancer therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the gastric cancer therapy industry. These gastric cancer therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Gastric cancer therapy encompasses the medical treatments aimed at managing and eradicating cancer that originates in the stomach lining. These treatments include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy, which may be used alone or in combination based on the disease’s stage and specific characteristics. The therapies function by killing rapidly dividing cancer cells, blocking molecular pathways that promote tumor growth, or activating the immune system to target cancer cells.

The primary categories of gastric cancer therapy are chemotherapy, targeted therapy, immunotherapy, radiation therapy, and surgery. Chemotherapy uses drugs to destroy rapidly dividing cancer cells throughout the body. These drugs are grouped into cytotoxic agents, monoclonal antibodies, tyrosine kinase inhibitors, checkpoint inhibitors, and other miscellaneous agents and can be delivered orally, intravenously, intramuscularly, or subcutaneously. These therapies are employed across various disease stages - including early, locally advanced, and metastatic and are used by multiple end users such as hospitals, oncology clinics, ambulatory surgical centers, research facilities, and home care providers.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.